SPACE (SPS ADVANCED CAGE): SPS Spacer for Intervertebral Fusion, Longitudinal, Prospective Clinical Study

SPS srl

Status

Not yet enrolling

Conditions

Treatment of Degenerative Diseases of the Spine

Treatments

Device: Intersomatic arthrodesis

Study type

Interventional

Funder types

Industry

Identifiers

NCT05828784

SPS101

Details and patient eligibility

About

Space clinical study aims to evaluate the performance, in terms of efficacy and safety of an intervertebral spacer associated with a bioceramic bone substitute in the context of intervertebral surgery for degenerative diseases.

Specifically, it is intended to evaluate:

the capacity for bone regeneration/fusion, defined as absence of loosening and presence of continuous trabecular bone bridge in the absence of radiolucency lines, verified by imaging (CT) and evaluated according to the Brantingan scale;
the safety of the medical device, through the incidence of any adverse events, complications, unexpected reactions, accidents;
the improvement of clinical outcome in terms of pain and disability, at 9/14 months follow-up compared with preoperative scores, by clinical indices such as ODI and VAS.

Enrollment

35 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have provided hospital consent for surgical treatment;
Male patients and non-pregnant female patients between the ages of 18 and 75 years;
Patients requiring single-level interbody fusion in the L3-L4 and L4-L5 tract;
Patients with degenerative diseases of the spine, such as lumbar canal stenosis, lumbar discopathy, degenerative spondylolisthesis grade I;
Patients with a BMI <= 30;
Patients physically and mentally willing and able to comply with postoperative indications;
Patient able to understand the Italian language;
If the investigator decides to fuse an additional level for spinal stability during surgery, this is not an exclusion criterion; however, only one level will be measured to comply with the surgical indication.
Female patients who are pregnant or planning to become pregnant during the course of the study;
Obese patients with a BMI index > 30.

Exclusion criteria

Patients with:

systemic or localized infection;
Inflammatory or autoimmune disease;
hypercalcemia;
coagulation disorders;
metabolic disorders;
insulin-dependent diabetes;
alterations or complications of thyroid function;
overt allergy to calcium phosphate salts;
self-reported allergies to drugs and/or medical devices;
tumor and/or infectious diseases of the spine;
active neoplasms;

In addition, patients who:

Abuse alcohol and drugs;
Are affected by smoking (> 20 cigarettes/day);
Are on drug therapy that causes alteration of bone regeneration (e.g., chemotherapy);
already had surgery (revision surgery).